Hannah Clarke

“The ADVANCED-2 trial in NMIBC is an exciting opportunity to build on the favorable anti-tumor and safety data of TARA-002 presented earlier this year," says Gautam Jayram, MD.

Patients with mCRPC will be randomly assigned 2:1 to receive masofaniten/enzalutamide or enzalutamide alone.

The supplemental new drug application is supported by findings from the LITESPARK-005 trial.

In total, the prospective SOPHIA study enrolled 6 men with stress urinary incontinence who have reduced outlet resistance due to intrinsic sphincter deficiency.

Both the LUTS/BPH and testicular cancer guidelines were updated based on the availability of new literature, as identified through an AUA Update Literature Review process.

"A lot of urologic associations have committed a lot of work to diversity, equity, and inclusion, and this just seems like a step backward compared with the policies that they've been working toward in diversifying the urologic work force," says Diana Magee, MD, MPH, MSc, FRCSC.

"The findings suggest that we may need to view urinary symptoms differently, possibly with an emphasis on earlier treatment,” says Blayne Welk, MD, FRCSC, MSc.

Patients with MIBC were randomly assigned to receive APL-1202 in combination tislelizumab or to tislelizumab alone.

"Our study is the first report of bladder auto-transplantation in heart-beating, brain-dead human research donors as a necessary preparatory step toward clinical bladder transplantation in living patients," says Inderbir S. Gill, MD.

Participants who completed a survey following the intervention indicated that the program was most helpful for networking with other applicants, finding a mentor, and serving as an introduction to urology.

The first patient with NMIBC has been dosed with nadofaragene firadenovec-vncg as part of the Adstiladrin Early Experience Program.

The phase 3 URO-901-3005 study met its 2 co-primary end points with vibegron demonstrating a reduction in micturition episodes and urgency episodes from baseline to 12 weeks.

Questions spanned urologic conditions such as benign prostatic hyperplasia, overactive bladder, erectile dysfunction, kidney stones, Peyronie disease, and recurrent urinary tract infections.

"This could make a huge impact for patients with limited resources,” says Benjamin Pockros, MD, MBA.

In this installment, Kevin Zorn, MD, FRCSC, FACS, highlights his disease-specific practice, BPH Canada, which he designates as a “one-stop shop” for patients with benign prostatic hyperplasia.

Men who had a dorsal testosterone/peripheral testosterone ratio greater than 2 were found to have higher rates of PSA persistence compared with patients who had a similar ratio.

The phase 1/2 Oncorella-1 trial is expected to enroll up to 40 patients with advanced kidney cancer who are on dialysis due to renal failure.

“Our findings show that AI chatbots provided accurate information with little misinformation. However, the information was provided at a college reading level and with little actionability," says Abdo E. Kabarriti, MD, FACS.

“A major finding from our study is how multiple sociodemographic, lifestyle, and medical factors influence testosterone levels in men," says Bu B. Yeap, MBBS, FRACP, PhD.

The authors suggest that metastasis-free survival may serve as a more suitable end point for future clinical trials of radiation therapy in localized prostate cancer.

About 30% of patients received a diagnosis of ED and prediabetes or type 2 diabetes on the same day.

The BioProtect Balloon Implant System provides protection to the rectum during radiation therapy for prostate cancer.

Cohort 3 of the SECuRE trial is exploring the safety and efficacy of a single-dose administration of 12GBq 67Cu SAR-bisPSMA in patients with metastatic castrate-resistant prostate cancer.

The signatures were derived from the Decipher Genomics Resource for Intelligent Discovery (GRID) database in a retrospective analysis of the phase 2 STREAM study.

"These results show urologists that in this setting, pregabalin shouldn’t be routinely used," says Geoffrey H. Rosen, MD.

"We found that urology practices increasingly using mpMRI, and tissue-based genomics to a lesser extent, are more likely to treat men who have a high risk of non-cancer mortality. These men have the least to gain from treatment and are likely being overtreated,” says Kassem S. Faraj, MD, MS.

"Our study raises concerns that some insurance plan policies are denying an effective, research-proven therapy, for a very common condition for which treatment is considered medically necessary," says Mohit Khera, MD, MBA, MPH.

In predicting PCSM at 10 years, the area under the curve with the P-score was 0.93, compared with 0.81 with D’Amico and 0.88 with CAPRA.

Patients in the CONTACT-02 trial were randomly assigned 1:1 to receive cabozantinib plus atezolizumab or a second novel hormonal therapy of either abiraterone and prednisone or enzalutamide.

Laura Bukavina, MD, MPH, highlights a BCAN Think Tank session on real-world applications of microbiome in bladder cancer.